| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -76,842 |
| Depreciation expense | 235 |
| Amortization expense | 207 |
| Share-based compensation expense | 8,160 |
| Net foreign exchange impacts | -10,792 |
| Other income, net | 2,600 |
| Income tax expense | 11 |
| Decrease/(increase) in trade receivables | -994 |
| Decrease/(increase) in other current assets | -7,757 |
| Decrease in r&d benefit receivable | -3,851 |
| Decrease in other long-term assets | -3,401 |
| (decrease)/increase in trade and other payables | -502 |
| Decrease in contract liabilities | -302 |
| Decrease in operating lease liabilities | -146 |
| Net cash provided by/(used in) operations | -44,984 |
| Redemption of term deposits | 98,036 |
| Purchase of term deposits | 92,635 |
| Purchase of property, plant and equipment | 55 |
| Net cash provided by/(used in) investing activities | 5,346 |
| Proceeds from issue of ordinary shares | 15 |
| Net cash provided by financing activities | 15 |
| (decrease)/increase in cash and cash equivalents | -39,623 |
| Cash and cash equivalents at beginning of period | 121,330 |
| Effect of exchange rate changes on cash | 324 |
| Cash and cash equivalents at end of period | 82,031 |
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)